
Herantis Pharma Investor Relations Material
Latest events

H2 2024
Herantis Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Herantis Pharma
Access all reports
Herantis Pharma Oyj is a Finnish biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases, particularly Parkinson's disease. The company's lead program centers around HER-096, a small synthetic chemical designed to mimic the activity of cerebral dopamine neurotrophic factor (CDNF). This treatment aims to address the progression of Parkinson's by protecting neurons and enhancing their function. The company is headquartered in Espoo, Finland, and its shares are listed on the Helsinki Stock Exchange.
Key slides for Herantis Pharma


Company Presentation
Herantis Pharma


Company Presentation
Herantis Pharma
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
HRNTS
Country
🇫🇮 Finland